Results 11 to 20 of about 22,562,840 (346)

Efficacy of Replacement and Anti-Platelet Therapies in a Patient with Severe Haemophilia A Undergoing Percutaneous Coronary Stent Implantation

European Journal of Case Reports in Internal Medicine, 2022
Introduction: Severe haemophilia A is characterized by serious factor VIII deficiency (biological activity
Dorina Cultrera, Sergio Cabibbo
doaj   +1 more source

Living, Caring, Learning – Early education, active lives and tailored treatment in haemophilia care

The Journal of Haemophilia Practice, 2023
Josipa, a haemophilia nurse in Croatia, describes how meeting 18-year-old twins with severe haemophilia A changed her views around joint health and activity in people with haemophilia.
Belev Josipa
doaj   +1 more source

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

Haemophilia, 2020
The efficacy and safety of recombinant factor VIII Fc fusion protein (rFVIIIFc) as an extended half‐life treatment for severe haemophilia A were demonstrated in the Phase 3 A‐LONG and Kids A‐LONG studies. Eligible subjects who completed A‐LONG and Kids A‐
B. Nolan, J. Mahlangu, I. Pabinger, G. Young, Barbara A. Konkle, C. Barnes, K. Nogami, E. Santagostino, K. J. Pasi, L. Khoo, B. Winding, Huixing Yuan, J. Fruebis, D. Rudin, J. Oldenburg   +14 more
semanticscholar   +1 more source

Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US

Haemophilia, 2020
Surgery is frequently required in persons with haemophilia A (PwHA). Emicizumab, a bispecific, humanized monoclonal antibody, bridges activated factor (F) IX and FX.
M. Lewandowska, N. Randall, N. Bakeer, J. Maahs, J. Sagar, A. Greist, A. Shapiro   +6 more
semanticscholar   +1 more source

Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy

Hepatology, EarlyView., 2022
Abstract Background and Aims Current liver‐directed gene therapies look for adeno‐associated virus (AAV) vectors with improved efficacy. With this background, capsid engineering is explored. Whereas shuffled capsid library screenings have resulted in potent liver targeting variants with one first vector in human clinical trials, modifying natural ...
Nadja Meumann, Marti Cabanes‐Creus, Moritz Ertelt, Renina Gale Navarro, Julie Lucifora, Qinggong Yuan, Karin Nien‐Huber, Ahmed Abdelrahman, Xuan‐Khang Vu, Liang Zhang, Ann‐Christin Franke, Christian Schmithals, Albrecht Piiper, Annabelle Vogt, Maria Gonzalez‐Carmona, Jochen T. Frueh, Evelyn Ullrich, Philip Meuleman, Steven R. Talbot, Margarete Odenthal, Michael Ott, Erhard Seifried, Clara T. Schoeder, Joachim Schwäble, Leszek Lisowski, Hildegard Büning   +25 more
wiley   +1 more source

Adherence to prophylaxis in adolescents and young adults with severe haemophilia: a qualitative study with healthcare professionals [PDF]

, 2020
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits ...
Hart, Daniel, Ryder, Nuala, Troop, Nicholas, Van-Os, Sandra   +3 more
core   +3 more sources

Comparison of perioperative practices for placement of central venous access devices (CVAD) in children with haemophilia

The Journal of Haemophilia Practice, 2022
In children with haemophilia (CwH), central venous access devices (CVADs) are frequently placed to aid in the delivery of factor concentrates. In those who develop inhibitors, CVADs also allow for easy venous access and facilitation of immune tolerance ...
Kwan Celia, Chan Anthony KC, Koh Pei Lin, Kadir Nur Insyirah Abdul, Decker Kay, Lim Chiew Ying, Lam Joyce Ching Mei   +6 more
doaj   +1 more source

Living, Caring, Learning – Trust and teamwork in patient care

The Journal of Haemophilia Practice, 2023
Marcela, a nurse specialist in Brazil, reflects on the importance of trust in the therapeutic relationship in achieving the best patient outcomes. She describes her experience with a patient with severe haemophilia A and an inhibitor. The patient was non-
Sisdelli Marcela Ganzella
doaj   +1 more source

Haemophilia and ageing [PDF]

British Journal of Haematology, 2018
SummaryAdvances in the development of effective and safe treatments for haemophilia over the last 50 years have resulted in a significant increase in the life expectancy of persons with haemophilia (PWH). The management of this new cohort of middle‐aged and elderly PWH is challenging because of the opposing risks of haemophilia and age‐related ...
Shapiro, S., Makris, M.
openaire   +3 more sources

Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study

Haemophilia, 2020
The prevalence of arthropathy in moderate haemophilia A (MHA) and B (MHB) is not well known.
Ragnhild J Måseide, E. Berntorp, J. Astermark, Anna Olsson, M. Bruzelius, T. Frisk, V. Nummi, R. Lassila, G. Tjønnfjord, P. Holme   +9 more
semanticscholar   +1 more source